PolyPeptide Group AG (SIX: PPGN) Investor presentation H2 2022

NH

NH2

8 September 2022



GLOBAL SUPPORT FOR A QUALITY SOLUTION

Disclaimer

This presentation (the "Presentation") has been prepared by PolyPeptide Group AG ("PolyPeptide" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on our website at <u>report.polypeptide.com/hyr/22/</u>.

PolyPeptide, together with its directors, officers, employees and advisors, make no representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the fairness, reasonableness, accuracy, or completeness or correctness of the information contained in the Presentation or of the views given or implied. PolyPeptide, together with its directors, officers, employees and advisors, shall have no liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this Presentation, its information or its contents or otherwise arising in connection therewith. PolyPeptide reserves the right to amend or replace the Presentation at any time and undertakes no obligation to provide the recipients with access to any additional information. Neither PolyPeptide, its directors, officers, employees or advisors nor any other person shall not be obligated to update or correct the information set forth in the Presentation (except as required by applicable laws and regulations). Nothing in this Presentation is, or should be relied upon as, a promise or representation as to the future.

To the extent available, the industry, market and competitive position data contained in this Presentation has come from third-party sources as referenced. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Group believes that each of these publications, studies and surveys has been prepared by a reputable source, the Group has not independently verified the data contained therein and there is no guarantee that such data has been verified by those sources. In addition, certain of the industry, market and competitive position data contained in this Presentation come from the Group's own internal research and estimates based on the knowledge and experience of the Group's management in the market in which the Group operates. While the Group believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this Presentation.

Forward-looking information

This Presentation has been prepared by PolyPeptide and includes forward-looking information and statements concerning the outlook for its business. These statements are based on current expectations, estimates and projections about the factors that may affect the Group's future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as 'expects', 'believes', 'estimates', 'targets', 'plans', 'projects', 'outlook' or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide's control, that could cause the Group's actual results to differ materially from the forward-looking information and statements made in this Presentation and which could affect the Group's ability to achieve its stated targets. Although PolyPeptide believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Alternative Financial Performance Measures (APM)

This Presentation contains references to operational indicators, such as customer projects, and alternative financial performance measures ("APM") that are not defined or specified by IFRS, including revenue at constant currency rates, EBITDA, adjusted EBITDA, adjusted EBITDA margin, net operating assets, return on net operating assets, capital expenditures, equity ratio, net working capital, free cash flow, net cash, total financial debt and revenue associated with the coronavirus pandemic. These APM should be regarded as complementary information to and not as substitutes of the Group's consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, refer to the section "Definitions and reconciliations" in PolyPeptide Group AG's Half Year Report 2022 available at <u>report.polypeptide.com/hyr/22/</u>.

Unaudited Financial Results

The financial information contained in this Presentation is unaudited.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF POLYPEPTIDE OR THE GROUP.



Agenda


1	Market overview
2	Company overview
3	Strategy
4	Performance & financial targets
5	Corporate Governance, calendar and contact



Peptide-based drugs market with structural growth momentum


Broad therapeutic areas with significant product pipeline

Estimated peptide therapeutics end market (\$ Bn)¹



¹Source: IMARC 2021, Peptide therapeutics market 2022-2027 ²Source: GlobalData, Drugs Database, (accessed 17 August 2022) **GLOBAL SUPPORT FOR A QUALITY SOLUTION**

~81 drugs FDA approvals and ~800 in development²



- Growth driven by a growing number of approved peptide drugs, growing patient population (cancer, metabolic disorders, etc.) and increasing genericization of key originator peptides.
- Broad therapeutical areas of application resulting in rich project pipeline globally
- Increasing number of expected API approvals for years to come



Addressable peptide API market of ~\$ 1.2 Bn

Continued trend towards outsourcing and specialization

Market structure¹



Outsourcing trends

- Innovative drug development processes resulting in rich pipelines across modalities
- Pharma and biotech customers to focus on core competencies, time to market and productivity
- Higher complexity of emerging peptide APIs, including shift towards chemical synthesis
- Evolving regulatory requirements and high capex requirements resulting in need for critical scale

CDMO success factors

Specialized technical expertise and know-how Berformance

Ability to meet evolving regulatory requirements Continued capacity building with high utilization

Reputation and market access for pipeline building Innovation mindset and high customer satisfaction




¹Based on a study commissioned by PolyPeptide and completed in early 2021

Agenda

1	Market overview
2	Company overview
3	Strategy
4	Performance & financial targets
5	Corporate Governance, calendar and contact



70+ years of experience in peptide manufacturing





Comprehensive services for complex peptides Supporting customers over product life cycle in three business areas



Pre-clinical and clinical phases I-III

Full spectrum manufacturing and associated CMC services supporting pre-clinical development.

Process designed in partnership with the customer to be scalable through the development process.



Contract manufacturing



Commercial, after regulatory approval

Expertise in process development, manufacturing scale-up, regulatory filings, and launch preparation.

Continuous yield improvement is key.



Generics and cosmetics



Generics with non-originator customers and cosmetics

Manufacture of a range of peptidebased generics and cosmetics at commercial scale for multiple customers.






~ 1'200 employees worldwide with deep knowledge

Network of six GMP-certified sites on three continents for services across development phases

- A global market leader for innovative clinical and commercial stage peptide drug substances
- Manufacturing around half of all approved peptide API's and strong custom project pipeline
- Long-term partner for customers, from biotech start-ups to large pharmaceutical companies



Employees by qualification and experience ¹



Footprint with customer proximity in Europe, the US and India¹



3 Malmö, Sweden 303 employees

4 Braine-l'Alleud, Belgium 410 employees

5 Strasbourg, France 134 employees

6 Baar, Switzerland (HQ) 6 employees

Ambernath, India 78 employees

PolvPeptide

¹Headcount as of 30 June 2022 **GLOBAL SUPPORT FOR A QUALITY SOLUTION**

Production sites overview (1/2)

Specialized facilities from experimental to large scale production¹

🛟 Malmö	Braine-l'Alleud	() Strasbourg	Torrance	👙 San Diego	Ambernath
Weight and the second	Site with largest liquid phase synthesis in operations, major solid phase capacity expansion ongoing; facility for all peptide batch sizes and all segments.	Special focus on innovation and cosmetics. Smaller facility for most peptide segments.	Mid-sized site, also servicing personalized medicine, handling most peptide batch sizes for all segments; lab space and pilot GMP facility to serve oligonucleotides.	Designed to efficiently handle smaller peptide batch sizes for all segments, incl. radio-labelled peptides.	Designed to handle generic peptides, manufactured mostly in mid-sized batches.
~12,800 m	~30,000 m	~6,100 m	~14,000 m	~4,800 m	~8,100 m
303 employees	410 employees	134 employees	203 employees	68 employees	78 employees
>30 years	>30 years	>20 years	>20 years	>20 years	>10 years
¹ Status September 2022; headcount as of 30 June 2022					



Production sites overview (2/2)

Specialized facilities from experimental to large scale production¹



¹Status September 2022






Agenda

1	Market overview
2	Company overview
3	Strategy
4	Performance & financial targets
5	Corporate Governance, calendar and contact



Integrated strategy






Start here – stay here

Providing expert knowledge for API's along product life cycle





Legend: API – Active pharmaceutical ingredient; CMC – Chemistry, manufacturing & controls; GMP – Good manufacturing practice;

ICH – International council for harmonization; LCM – Life cycle management; NDA – New drug application; PPQ – Process performance qualification

GLOBAL SUPPORT FOR A QUALITY SOLUTION




Go for growth

Core peptide segment expected to remain a growth driver

Increasing use of peptides across a diverse set of indications and medical conditions

- Longer and more complex peptides
- Cocktail of peptides
- Pegylation and conjugation
- Cell penetrating peptides as carriers





- Peptide market expected at USD 62bn by 2027²
- Continued R&D investments into peptides by big pharma and biotech, currently ca.³
 - 81 FDA approvals
 - 800 in development
- Increasing expected number of peptides losing patent in the next decade, further fueling growth of the peptide API generics market

¹Number of peptide drugs approvals in respective period; source: Muttenthaler et al., Trends in peptide drug discovery, Nature Reviews Drug Discovery 20, 309–325 (Feb 2021) ² IMARC 2021, Peptide therapeutics market 2022-2027 ³Source: GlobalData, Drugs Database, (accessed 17 August 2022)





Go for growth New capabilities in oligonucleotides¹



Addressing unmet customer needs in oligonucleotide modality given increasing therapeutic relevance

- R&D and GMP pilot plant facility up and running
- Dedicated team
- First customer project started
- Building of portfolio of early-stage custom projects

Committed to providing capacity

- First Building R&D and GMP pilot plant
 - 2 small scale and 1 medium scale lines on site and operational
 - Adding additional lines to triple throughput
- Second Building evaluation of site expansion ongoing
 - Engineering study completed to potentially add large scale process lines for multikg batch production



GMP pilot plant purification suite in Torrance, California




¹Status March 2022

Drive innovation



Multi-faceted comprehensive green chemistry program to reduce environment footprint





Drive innovation



Improving cost, time, quality







- Advanced monitoring automation
- Improved automated processes for peptide synthesis and purification

Alternative isolation technologies

- In silico predictive tools
- MES

•

•

LIMS

Flow chemistry

Mechanochemistry

Electrochemistry

Innovative analytics

Particle analysis

Culture of innovation

- · Innovation culture being embedded in the organization
- Global "Innovation and Technology " group in Strasbourg and Torrance
- Go from idea to concept all the way to deployment at scale
- · Incubator for new business (services and product) ideas

Established external collaborations network





GLOBAL SUPPORT FOR A QUALITY SOLUTION

Braine-l'Alleud

OnePolyPeptide

Malmö

Improving processes, systems and platforms across the Group for sustainable growth

Strasbourg



19

Torrance

San Diego



Ambernath



Responsible partnerships

Material ESG topics and ESG agenda as integral part of business strategy



Twelve material ESG topics

Sustainability partner

- Green chemistry
- Circular waste management
- Environmental protection
- Climate change mitigation

Employer of choice

- People development
- Employee health
- Diversity & inclusion

Business excellence

- Supply chain engagement
- Product quality
- Stakeholder dialogue
- Data protection
- Ethics & compliance

Established ESG agenda 2022+

- First focus on
 - Green chemistry
 - People development
 - Supply chain engagement
- Development of specific ESG targets
- Broadening of CO₂ footprint assessment
- Broadening of various certification programs
- Decision on reporting standard for FY 2023



Five-step

materiality

assessment

Agenda

1	Market overview
2	Company overview
3	Strategy
4	Performance & financial targets
5	Corporate Governance, calendar and contact



EBIT and result for half year

Result for the period down by 58.4% with basic EPS of € 0.31

Summary P&L € m

	H1 2018	H1 2019	H1 2020	H1 2021	H1 2022
Revenue	81.6	90.7	87.8	135.1	133.7
EBITDA	20.6	22.7	18.5	39.9	26.7
margin %	25.2%	25.0%	21.1%	29.5%	20.0%
D&A	-6.8	-7.5	-8.4	-9.1	-11.2
Operating result	13.8	15.2	10.2	30.8	15.5
margin %	16.9%	16.8%	11.6%	22.8%	11.6%
Net financial result	-0.6	-0.9	-0.9	-1.3	-2.6
Income tax charges	-2.8	-2.9	-1.5	-4.9	-2.6
Result for the period	11.6	11.4	7.8	24.6	10.2
margin %	14.2%	12.6%	8.9%	18.2%	7.7%

H1 2022 margins

- EBITDA margin of 20.0%
- EBIT margin of 11.6%
- Net profit margin of 7.7%

H1 2022 tax rate of 20.2%

Basic earnings per share (EPS) of € 0.31




Revenue and reported EBITDA

H1 2022 results in the context of historical trends, partly affected by the coronavirus pandemic

Revenue € m

Reported EBITDA € m



H1 2022 revenue of € 133.7 m, YoY -1.1%

or -3.3% at constant currency rates

- Original plan for broadly stable revenue
- Challenges within a more demanding market environment, with several deliveries slipping into H2


H1 2022 EBITDA of € 26.7 m, YoY -33.1%

- Larger-than-expected drop, driven mostly by amplified inflationary pressure but also by operational challenges
- Strong PY period
- Increased personnel cost ahead of growth



Revenue by business area


Reported Group revenue broadly stable across business areas





Capital expenditures

Continued capacity expansion, but also new capabilities, digitalization and modernization




¹ Capital expenditures defined as investments in intangible assets and property, plant and equipment capitalized during the reporting period



GLOBAL SUPPORT FOR A QUALITY SOLUTION

Updated guidance for 2022

Reduced guidance – growth and partial margin recovery in H2 driven by peptides business






Updated mid-term outlook

Revenue CAGR in low-teens, expectation of varying yoy growth rates

Revenue € m

Revenue CAGR in low-teens with varying growth rates year-on-year and adj. EBITDA margin progression towards 30%



Considerations

- Structural market trends
- Custom projects portfolio
- Uneven phasing
- Coronavirus pandemic
- Macroeconomic environment
- Geopolitical situation



GLOBAL SUPPORT FOR A QUALITY SOLUTION

Agenda

1	Market overview
2	Company overview
3	Strategy
4	Performance & financial targets
5	Corporate Governance, calendar and contact



PMC – PolyPeptide Management Committee



Raymond De Vré ∆ Belgian, CEO



Jon Holbech Rasmussen Danish, Director Global Development, IP and Regulatory



Neil Thompson ∆ British, Director Global Sales and Marketing



Landon Piluso American, Director Global Quality



Daniel Lasanow Δ Belgian, Director Global Operations



Olivier Ludemann-Hombourger French, Director Global Innovation and Technology



Christina Del Vecchio ∆ Swiss / Swedish, General Counsel



Monika Casanova German, Chief HR Officer (from May 2022)



Jan Fuhr Miller Δ Danish, CFO



Michael Stäheli Swiss, Head IR / Corporate Communications / ESG



Board of Directors

Chairman and members appointed in 2021 in context of IPO



Peter Wilden German Chairman



Philippe A. Weber Swiss Independent Member



Jane Salik American Member



Beat In-Albon ▲ Swiss Independent Member



Erik Schropp O Dutch Member



Patrick Aebischer Swiss Independent Member

Chair △ Member O Remuneration & nomination committee Innovation & technology committee Audit & risk committee

The Board of Directors is responsible for PolyPeptide's overall direction and oversight of management, and holds the ultimate decision-making authority, with the exception of matters reserved for shareholders.

> Visit our website or the section Corporate Governance in the Annual Report 2021 for the detailed CV's

polypeptide.com

report.polypeptide.com/ar/21/board-of-directors/



IR contact and financial calendar

Investor Relations team

Michael Stäheli Head of Investor Relations & Corporate Communications Phone: +41 (0) 41 723 20 34 / <u>michael.staeheli@polypeptide.com</u>

Julia Jaun Investor Relations / ESG Manager Phone: +41 (0) 41 723 20 40 / julia.jaun@polypeptide.com

investorrelations@polypeptide.com polypeptide.com/investors

Share information

PolyPeptide Group AG has been listed on the Swiss Stock Exchange (SIX) since 29 April 2021 under the symbol SIX: PPGN, Swiss security number 111 076 085 and ISIN CH111 076 085

Share register

areg.ch ag Fabrikstrasse 10, 4614 Hägendorf, Switzerland Phone: +41 (0) 62 209 16 60 / <u>info@areg.ch</u>

Selected events in 2022

07 - 09.09.22	UBS Best of Switzerland Conference, Ermatingen, Switzerland
12.09.2022	Morgan Stanley Global Healthcare Conference, New York, USA
15 - 16.09.22	Bank of America European Healthcare Conference, London, UK
21.09.2022	Investora conference, Zurich, Switzerland
03.10.2022	RBC Capital Markets Virtual Pharmaceutical CDMO conference
04.11.2022	ZKB Swiss Equity Conference, Zurich, Switzerland
15 - 16.11.22	Jefferies London Healthcare Conference, London, UK
17.11.2022	Credit Suisse Equity Forum Switzerland, Zurich, Switzerland

Corporate events in 2023

14.03.2023	FY 2022 results
12.04.2023	AGM 2023
15.08.2023	HY 2023 results

Visit our website for the detailed event calendar polypeptide.com



Analyst coverage







- Morgan Stanley
 - OCTAVIAN

• James P. Quingly

Patrick Wood

Beatrice Allen

Tanya Hansalik

•

٠

•

- Laura Pfeifer-Rossi
- Daniel Buchta

- +44 20 7995 7035, patrick.wood@bofa.com
- +44 20 3465 2662, <u>beatrice.allen@berenberg.com</u>
 - +41 44 334 22 10, tanya.hansalik@credit-suisse.com
- +44 20 7677 1963, james.quingly@morganstanley.com
- +41 44 520 06 19, <u>laura.pfeifer-rossi@octavian.ch</u>
 - +41 44 292 37 34. <u>daniel.buchta@zkb.ch</u>



Zürcher Kantonalbank

THANK YOU

01240